Apexigen Announces Appointment of Dr. Frank Hsu as Chief Medical Officer

NEXT STORY
Beroni Group Received Approval for 43.5% R&D Rebate from Australian Government for the Novel, Potential Anti-Cancer Drug PENAO
PREV STORY
Le Dr Benjamin Musher présidera l’étude de phase 1-2 évaluant le traitement anticancéreux Natrunix™ de XBiotech contre le cancer du pancréas
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Helsinn Group announces the launch of the IV formulation of AKYNZEO® (fosnetupitant/palonosetron) in the United States

Helsinn Group announces the launch of the IV formulation of AKYNZEO® (fosnetupitant/palonosetron) in the ...

author_avatar
NASDAQ Market News

ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit

BOSTON, Sept. 01, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused ...

author_avatar
NASDAQ Market News

Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the European Society for Medical Oncology 2018 Congress

BERKELEY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today ...

author_avatar
NASDAQ Market News